Alzheimer's: Page 2

AI-driven method developed to identify therapeutic targets

By Matt Limb

Researchers have developed a method of identifying therapeutic targets for human diseases associated with protein phase separation that they say could be used to discover targets for Alzheimer’s and other neurogenerative diseases.

October 17, 2023

Protein panel improves Alzheimer’s diagnosis, predictions of disease progression

By Nick Paul Taylor

Quantifying certain proteins in cerebrospinal fluid could improve the diagnosis of Alzheimer's disease and prediction of disease progression, according to a paper in Science Translational Medicine.

October 3, 2023

Alzheimer’s drug approval poised to reshape APOE testing market

By Nick Paul Taylor

The U.S. Food and Drug Administration (FDA) approval of Biogen and Eisai’s Alzheimer’s disease drug Leqembi is likely to drive changes in the APOE testing market, according to an article in GenomeWeb.

September 25, 2023

Experts raise concerns about Quest Diagnostics’ consumer-initiated Alzheimer’s test

By Nick Paul Taylor

Experts have raised concerns about Quest Diagnostics’ $399 consumer-initiated Alzheimer’s disease test, telling 360Dx that it is unclear whether the product is accurate enough to support its use.

September 15, 2023

C2N Diagnostics rolls out second-generation Alzheimer's disease biomarker test

By Matt Limb

C₂N Diagnostics has unveiled its “next generation” blood biomarker test to evaluate patients with signs and symptoms of Alzheimer’s disease (AD) and other causes of cognitive decline.

August 29, 2023

Exploratory trial links kinase inhibitor to epigenetic changes in dementia patients

By Nick Paul Taylor

Results from a clinical trial show that a small molecule that binds to kinases involved in inflammatory signaling may induce epigenetic changes in people with mild cognitive impairment and probable Alzheimer’s disease.

August 22, 2023

Quest Diagnostics launches consumer-initiated Alzheimer’s risk assessment test

By LabPulse.com staff writers

The new test uses the same technology as Quest's clinical AD-Detect Amyloid Beta 42/40 Ratio biomarker test for assessing amyloid beta protein, a recognized marker for Alzheimer’s, which was made available for physicians in early 2022.

August 1, 2023

Cumulus Neuroscience partners with U.K. universities on cognition test for early Alzheimer’s diagnosis

By Matt Limb

The partnership will look to scale the development and testing of the Fastball EEG test, which uses an EEG headset to measure brain activity while patients watch a series of flashing images displayed on a tablet or smartphone screen.

July 25, 2023

DiamiR Biosciences partners with JADBio on diagnostic tests, validation for biomarker panels

By Matt Limb

Under the deal, DiamiR will apply the capabilities of JADBio’s Automated Machine Learning (AutoML) bioinformatics platform and services to its own microRNA platform.

July 12, 2023

Roche receives FDA clearance for test to accelerate diagnosis of Alzheimer’s

By Nick Paul Taylor

The new 510(k) clearance covers two tests that run on Roche’s Elecsys immunoassay system. One of the assays, which measures beta-amyloid, was part of the 510(k) clearance that Roche received last year.

June 29, 2023

Biotech firm AltPep closes $53M Series B financing round

By LabPulse.com staff writers

AltPep said that the proceeds from the round will be used to accelerate its Sobin therapeutics for Alzheimer’s and Parkinson’s diseases into phase I clinical trials, as well as to advance its Soba diagnostic blood-based assay for Alzheimer’s disease.

June 23, 2023

Alzheimer’s and encephalopathy linked to eye biomarkers

By Elissa Wolfson

Study finds Alzheimer's disease and chronic traumatic encephalopathy cases are linked to biomarkers present in the eye’s vitreous humor.

June 20, 2023

Previous Page

Page 2 of 8

Next Page